Browse by Industry
Filter News
Found 91,736 articles
-
The drug, a combination of cabotegravir and rilpivirine, is a complete therapy for HIV-1 infection in adults who are virologically suppressed.
-
One year and more than 410,000 deaths later, the United States is still firmly in the grips of the COVID-19 pandemic.
-
A Look at This Week’s Biotech IPOs
1/22/2021
The 2021 trend of biotech initial public offerings (IPOs) continued this week. Here’s a look. -
With the Pfizer-BioNTech and Moderna COVID-19 vaccines currently authorized in the U.S. and being distributed and dosed, some of the attention is shifting to Johnson & Johnson’s efforts for its one-shot vaccine.
-
GSK has discontinued a Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody aimed at treating ulcerative colitis licensed from Immutep Limited following an interim assessment of an Independent Data Monitoring Committee.
-
BioSpace Movers & Shakers, Jan. 22
1/22/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Ten pharmaceutical companies have joined forces again to launch Accumulus Synergy Inc., a non-profit effort to pool data in the cloud and interact with regulators, in the hopes of speeding the drug approval process.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
FSD Pharma Sets Date for Annual Meeting
1/22/2021
FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (“FSD Pharma” or the “Company”) today announced that it will hold its annual meeting of shareholders (the “Meeting”) on June 29, 2021. The Meeting will address normal course matters, including the presentation of the Company’s audited financial statements, as well as matters contained in a requisition for a special meeting submitted to the Company by certain shareholders of the Compa
-
Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine
1/22/2021
Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has finalized an agreement with the Government of Canada to supply up to 76 million doses of NVX-CoV2373, the company’s recombinant protein-based COVID-19 vaccine. Canada has committed to purchase 52 million doses of the vaccine with the option for up to an additional 24 million doses.
-
Amyris Acquiring Terasana Brand To Offer Clean Cannabinoid Consumer Products
1/22/2021
Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced that it will expand its portfolio of consumer brands by launching a new range of Terasana
-
/R E P E A T -- Notice to the media - COVID-19 Update (January 22, 2021) - Ministers and Government of Canada officials to hold a news conference on coronavirus disease/
1/22/2021
Ministers and Government of Canada officials will hold a news conference to provide an update on coronavirus disease (COVID-19). Date January 22, 2021 Time 12:30 PM (EST) Location The news conference will be held virtually. Journalists who wish to ask questions can do so by teleconference. Toll-free ( Canada /US) di
-
Revance Issues Inaugural Environmental, Social and Governance (ESG) Report
1/22/2021
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the release of its inaugural ESG Report, which details the company’s commitments and efforts to build strong corporate governance, and operate sustainably and responsibly, including its response to the COVID-19 pandemic and prevailing social issues in 2020.
-
Havn Life Sciences Announces Inclusion in First Psychedelic Exchange Traded Fund
1/22/2021
Havn Life Sciences Inc. (CSE: HAVN )(OTC PINK: HAVLF )(FSE: 5NP ) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it will be included in the First Psychedelics Exchange Traded Fund. The ETF will begin traded on the Neo Exchange on January 26, 2021.
-
Biotechnology Institute Launches BioDiversity Winter Institute
1/22/2021
This week, the Biotechnology Institute announced the launch of a new online afterschool STEM education program “BioDiversity” for 3 rd – 8 th graders. The fundamental objective of BioDiversity is to engage, excite and educate students of ethnic and cultural backgrounds that are under-represented in the scientific community about their potential to successfully pursue career paths in science.
-
Nanoform's Clinical Study Indicates Positive Interim Results - Jan 22, 2021
1/22/2021
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, announced positive interim results from its clinical study.
-
Senseonics Holdings Increases Previously Announced Bought Deal Offering of Common Stock to $100.0 Million
1/22/2021
Senseonics Holdings, Inc. announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 51,948,052 shares of common stock of the Company at a public offering price of $1.925 per share, less underwriting discounts and commissions.
-
DWHP Announces Extension of The Expiration Time of Its Tender Offer
1/22/2021
DW Healthcare Partners V, L.P., announced that it is extending the expiration time of its previously announced cash tender offer in the Offer to Purchase dated December 21, 2020 for all of the outstanding ordinary shares of Parnell Pharmaceuticals Holdings Ltd at a price of U.S.$0.40 per share, net to the seller in cash without interest and less applicable withholding taxes to 11:59 p.m., New York City time, on January 28, 2021.
-
Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for Patients with Severe COVID-19
1/22/2021
Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response therapeutics for the treatment of cancer, announced that the first patient has enrolled into an investigator-initiated trial of its investigational drug, Silmitasertib, as a treatment for hospitalized COVID-19 patients at Banner Health-University Medical Center in Phoenix, Arizona.
-
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
1/22/2021
CABENUVA offers adults living with HIV a new once-monthly injectable option for maintaining viral suppression